Browsing: SABCS

Welcome to OncologyTube’s SABCS Page! Here, we present the latest videos, expert interviews, and key insights from the San Antonio Breast Cancer Symposium (SABCS). Explore groundbreaking research, treatment strategies, and highlights from SABCS events—all designed for healthcare professionals like you. Stay updated with the most current advancements in breast cancer care, delivered straight from the forefront of this critical field!

Breast Cancer New Nemeses: CDK4/6 Inhibitors Rave Against Recurrence, But Have They Crashed the EBC Party in NATALEE & monarchE’s Real-World Dance-Off?

Breast 3 Mins Read

In his analysis, Paolo Tarantino, MD, delves into the transformative potential of CDK4/6 inhibitors in breast cancer therapy. He questions whether these drugs, celebrated for their promise in clinical trials, have truly matched expectations in real-world scenarios, specifically referencing data from the NATALEE and monarchE trials. The discussion is visually represented by a superhero figure donning a CDK4/6 emblem, symbolizing the hope and power these inhibitors bring to the fight against breast cancer. This image captures the essence of current medical debates surrounding the efficacy and application of these treatments in managing breast cancer recurrence and overall patient outcomes.

ctDNA: ZEST Trial Cleans Up Breast Cancer Treatment – Niraparib (ZEJULA) vs. Placebo in High-Risk TNBC and BRCA-Mutated Patients

Breast 3 Mins Read

The ZEST trial marks a pivotal moment in oncology, focusing on circulating tumor DNA (ctDNA) surveillance to detect molecular residual disease in breast cancer patients. This study explored whether Niraparib, a PARP inhibitor, could extend disease-free survival in patients with detectable ctDNA post-treatment but without visible signs of recurrence. The findings offer insights into both the potential and the limitations of using ctDNA for personalized cancer management.